Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People
- 18 November 2019
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 43 (2), 411-417
- https://doi.org/10.2337/dc19-1061
Abstract
OBJECTIVE The long-term influences of sex hormone administration on insulin sensitivity and incretin hormones are controversial. We investigated these effects in 35 transgender men (TM) and 55 transgender women (TW) from the European Network for the Investigation of Gender Incongruence (ENIGI) study. RESEARCH DESIGN AND METHODS Before and after 1 year of gender-affirming hormone therapy, body composition and oral glucose tolerance tests (OGTTs) were evaluated. RESULTS In TM, body weight (2.8 ± 1.0 kg; P < 0.01), fat-free mass (FFM) (3.1 ± 0.9 kg; P < 0.01), and waist-to-hip ratio (−0.03 ± 0.01; P < 0.01) increased. Fasting insulin (−1.4 ± 0.8 mU/L; P = 0.08) and HOMA of insulin resistance (HOMA-IR) (2.2 ± 0.3 vs. 1.8 ± 0.2; P = 0.06) tended to decrease, whereas fasting glucose (−1.6 ± 1.6 mg/dL), glucose-dependent insulinotropic polypeptide (GIP) (−1.8 ± 1.0 pmol/L), and glucagon-like peptide 1 (GLP-1) (−0.2 ± 1.1 pmol/L) were statistically unchanged. Post-OGTT areas under the curve (AUCs) for GIP (2,068 ± 1,134 vs. 2,645 ± 1,248 [pmol/L] × min; P < 0.01) and GLP-1 (2,352 ± 796 vs. 2,712 ± 1,015 [pmol/L] × min; P < 0.01) increased. In TW, body weight tended to increase (1.4 ± 0.8 kg; P = 0.07) with decreasing FFM (−2.3 ± 0.4 kg; P < 0.01) and waist-to-hip ratio (−0.03 ± 0.01; P < 0.01). Insulin (3.4 ± 0.8 mU/L; P < 0.01) and HOMA-IR (1.7 ± 0.1 vs. 2.4 ± 0.2; P < 0.01) rose, fasting GIP (−1.4 ± 0.8 pmol/L; P < 0.01) and AUC GIP dropped (2,524 ± 178 vs. 1,911 ± 162 [pmol/L] × min; P < 0.01), but fasting glucose (−0.3 ± 1.4 mg/dL), GLP-1 (1.3 ± 0.8 pmol/L), and AUC GLP-1 (2,956 ± 180 vs. 2,864 ± 93 [pmol/L] × min) remained unchanged. CONCLUSIONS In this cohort of transgender persons, insulin sensitivity but also post-OGTT incretin responses tend to increase with masculinization and to decrease with feminization.Keywords
This publication has 41 references indexed in Scilit:
- Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 DiabetesDiabetes Care, 2011
- Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study)Diabetes Care, 2011
- Sex Steroids Affect Triglyceride Handling, Glucose-Dependent Insulinotropic Polypeptide, and Insulin SensitivityDiabetes Care, 2010
- Incretin levels in polycystic ovary syndromeActa Endocrinologica, 2008
- Pancreatic Insulin Content Regulation by the Estrogen Receptor ERαPLOS ONE, 2008
- Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation TherapyJournal of Clinical Oncology, 2006
- Sex Differences of Endogenous Sex Hormones and Risk of Type 2 DiabetesJAMA, 2006
- Effect of hormone therapy on the enteroinsular axisMenopause, 2005
- The Effects of Varying Doses of T on Insulin Sensitivity, Plasma Lipids, Apolipoproteins, and C-Reactive Protein in Healthy Young MenJournal of Clinical Endocrinology & Metabolism, 2002
- The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women.JCI Insight, 1998